Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Targretin bexarotene capsules: Phase II/III data; NDA and MAA under review

In a 58-patient Phase II/III trial, 15 of 28 patients receiving 300

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE